• $32.4M
    Market Cap
  • -33.12%
    1-Year Change
  • Drug Manufacturers - Specialty & Generic
    Industry

Key Performance

More
  • Earnings Score: N/A
  • Momentum Score: 37
  • True Yield: N/A
  • Financial Health Score: N/A
TradeSmith Loading

Latest Research & News

InterCure Receives Nasdaq Notification Regarding Minimum Bid Requirement

InterCure Ltd. (Nasdaq: INCR) received a notice from Nasdaq on February 25, 2026, indicating non-compliance with the minimum bid price requirement of $1.00 per share. The company has been granted a 180-calendar day compliance period until August 24, 2026, to regain compliance. InterCure plans to consider a reverse share split as part of its strategy to meet the requirement. The company's shares will continue trading on Nasdaq during this period.

03/03/2026, 4:46 PM • GlobeNewswire

InterCure Announces Preliminary Estimated 2025 Revenue of NIS 265 Million, Positive Adjusted EBITDA and Cash of NIS 43 Million

InterCure reported preliminary 2025 revenue of NIS 265 million, representing 11% growth year-over-year with nearly 20% growth in H2 2025. The company achieved its twelfth consecutive half-year of positive Adjusted EBITDA and generated first significant revenues from the German market. The company also announced strategic acquisitions of Botanico Ltd. and a 28% stake in Cannasoul R&D Ltd., along with NIS 81 million in war-related compensation advances from Israeli authorities.

02/19/2026, 7:00 AM • GlobeNewswire

InterCure Enters Premium US Cannabis Market With ISHI Deal

InterCure Ltd. announced its acquisition of Botanico Ltd. (ISHI), gaining access to advanced AI-driven cultivation technologies and exclusive US cannabis brand partnerships, positioning itself for potential industry expansion amid potential cannabis rescheduling.

09/19/2025, 10:06 AM • Benzinga

Peers

  • CAMP
    CAMP4 THERAP
    $4.17+4.77%
    Market Cap$228.0M
    1-Year Change+105.15%
  • UNCY
    UNICYCIVE THERAP
    $7.20-0.41%
    Market Cap$197.0M
    1-Year Change-5.24%
  • FOCL
    EDAP TMS ADR
    N/AN/A
    Market Cap$161.9M
    1-Year ChangeN/A
  • ASRT
    Assertio Hldgs
    $23.42-0.13%
    Market Cap$151.5M
    1-Year Change+133.30%
  • AMWL
    AMERICAN WELL-A
    $8.46-0.47%
    Market Cap$148.1M
    1-Year Change+23.01%
  • CRDL
    CRD-A-144A-S-AI
    $1.25+8.70%
    Market Cap$140.6M
    1-Year Change-12.21%
  • BMEA
    BIOMEA FUSION
    $1.30-5.11%
    Market Cap$99.8M
    1-Year Change-44.98%
  • FBIO
    FORTRESS BIOTCH
    $2.57-3.02%
    Market Cap$93.0M
    1-Year Change+44.02%
  • HYFT
    MINDWALK HLDG
    $1.80-8.63%
    Market Cap$82.2M
    1-Year ChangeN/A

Statistics

More
Day Range
$1.02
$1.09
$1.03
1-Year Range
$0.73
$1.73
$1.03
Latest Close$1.03
Change
-$0.04 (-3.88%)
Volume40,266
Market Cap$32.4M
Shares Outstanding27.0M
P/E (TTM)-1.82
Diluted EPS (TTM)-$0.66
Enterprise Value$74.8M

Information as of 06/02/2026

Company Profile

INTERCURE LTD
https://www.intercure.co
$32.4M
Market Cap
-$36.8M
Net Income
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
85 Medinat ha-Yehudim Street, Herzliya, Israel, 4676670
972 7 746 05012

InterCure Ltd., together with its subsidiaries, engages in the research, cultivation, production, marketing, and distribution of pharmaceutical-grade cannabis and cannabis-based products for medical use in Israel and internationally. The company offers dried cannabis inflorescences and cannabis extract mixed with oil. It also invests in the biomed sector. The company has a strategic alliance with Cannasoul R&D Ltd. for the research, development, and commercialization of evidence-based cannabis therapeutics. The company was incorporated in 1994 and is headquartered in Herzliya, Israel.

Key Executives

  • Amos Cohen
  • Alexander Rabinovich
  • Einat Zehavi
  • Itai Kabiljo

Current Ownership Distribution

  • Insiders74.5M (61.12%)
  • Institutions39.7M (32.57%)
  • Mutual Funds7.7M (6.31%)
  • Other0 (0.00%)